Although the clinical utility of immune checkpoint inhibitors (ICIs) is well established in solid tumors, conventional ICIs such as PD-1/PD-L1 and CTLA-4 inhibitors have shown limited efficacy in MM. This evidence concerns the gene CD274 and Miyoshi myopathy.